The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gene Editing for CEP290 -Associated Retinal Degeneration
Open accessAbstract
Background CEP290 -associated inherited retinal degeneration causes severe early-onset vision loss due to pathogenic variants in CEP290 . EDIT-101 is a clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9 (Cas9) gene-editing complex designed to treat inherited retinal degeneration caused by a specific damaging variant in intron 26 of CEP290 (IVS26 variant). Methods We performed a phase 1–2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290 -associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye. The primary outcome was safety, which included adverse events and dose-limiting toxic effects. Key secondary efficacy outcomes were the change from baseline in the best corrected visual acuity, the retinal sensitivity detected with the use of full-field stimulus testing (FST), the score on the Ora–Visual Navigation Challenge mobility test, and the vision-related quality-of-life score on the National Eye Institute Visual Function Questionnaire–25 (in adults) or the Children’s Visual Function Questionnaire (in children). Results EDIT-101 was injected in 12 adults 17 to 63 years of age (median, 37 years) at a low dose (in 2 participants), an intermediate dose (in 5), or a high dose (in 5) and in 2 children 9 and 14 years of age at the intermediate dose. At baseline, the median best corrected visual acuity in the study eye was 2.4 log 10 of the minimum angle of resolution (range, 3.9 to 0.6). No serious adverse events related to the treatment or procedure and no dose-limiting toxic effects were recorded. Six participants had a meaningful improvement from baseline in cone-mediated vision as assessed with the use of FST, of whom 5 had improvement in at least one other key secondary outcome. Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test. Six participants had a meaningful improvement from baseline in the vision-related quality-of-life score. Conclusions The safety profile and improvements in photoreceptor function after EDIT-101 treatment in this small phase 1–2 study support further research of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine and others; BRILLIANCE ClinicalTrials.gov number, NCT03872479 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The doses of AAV vectors that have been used in retinal gene therapy trials have ranged from ~1 × 10 8 (Heier et al., 2017) up to ~3 × 10 12 vg/eye (Yang et al., 2022; Pierce et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Pierce et al., 2024
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, EDIT-101 has demonstrated a positive safety profile and variable effectiveness of visual functional outcomes (retinal sensitivity, visual acuity, Ora–Visual Navigation Challenge) in Phase 1/2 of a small cohort of 14 participants ( NCT03872479 ), 64 which is ongoing with a larger cohort (34 participants) to confirm efficacy ( Table 1 ).”
From Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches (2025) · cites this paper as [64]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a groundbreaking first-in-human study, EDIT-101 (Editas, Cambridge, Massachusetts, USA), comprising an AAV5 vector encoding Staphylococcus aureus Cas9 and two guide RNAs targeting CEP290 associated with LCA, was well tolerated at relatively high vector doses (Pierce et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Pierce et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Mutations in the CEP290 (NPHP6) Gene Are a Frequent Cause of Leber Congenital Amaurosis
den Hollander, A. I., Koenekoop, R. K., Yzer, S., López, I., Arends, M. L., Voesenek, K., Zonneveld, M. N., Strom, T. M., Meitinger, T., Brunner, H. G., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/507318 · Cited by 669
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461
Self-citationWorldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408
Cehajic-Kapetanovic, J., Xue, K., Martinez-Fernandez de la Camara, C., Nanda, A., Davies, A., Wood, L. J., Salvetti, A. P., Fischer, M. D., Aylward, J. W., Barnard, A. R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0763-1 · Cited by 368
Self-citationParfitt, D. A., Lane, A., Ramsden, C. M., Carr, A. F., Munro, P., Jovanovic, K., Schwarz, N., Kanuga, N., Muthiah, M. N., Hull, S., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.03.021 · Cited by 314
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Csaky, K. G., Richman, E. A., & Ferris, F. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1132 · Cited by 265
Clinical Characteristics and Current Therapies for Inherited Retinal DegenerationsPreprint
Sahel, J., Marazova, K., & Audo, I. S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 249
Research works printed but not linked: 1
- Pierce EA Ashimatey BS Jayasundera T et al. Twelve-month natural history study of CEP290-associated retinal degeneration. Ophthalmol Sci (in press) (https://www.ophthalmologyscience.org/article/S2666-9145(24)00019-8/pdf).
Cited by
Sorted by citations
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 152
Ling, S., Zhang, X., Dai, Y., Jiang, Z., Zhou, X., Lu, S., Qian, X., Liu, J., Selfjord, N., Şatır, T. M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01851-7 · Cited by 98
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 88
Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects
Cetin, B., Erendor, F., Ekşi, Y. E., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2025.10 · Cited by 80
Cavazza, A., Molina-Estévez, F. J., Reyes, Á. P., Ronco-Díaz, V., Naseem, A., Malenšek, Š., Pečan, P., Santini, A., Heredia, P., Aguilar-González, A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102457 · Cited by 78
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 51
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids
Furusho, T., Das, R., Hakui, H., Sairavi, A., Adachi, K., Galbraith-Liss, M. S., Rajagopal, P., Horikawa, M., Luo, S., Li, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54475-9 · Cited by 44
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 33
Self-citationRaigani, M., Eftekhari, Z., Adeli, A., & Kazemi‐Lomedasht, F. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102666 · Cited by 36
Gene Therapies in Clinical Development to Treat Retinal Disorders
McClements, M. E., Elsayed, M. E. A. A., Major, L., de la Cámara, C. M.-F., & MacLaren, R. E. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00722-0 · Cited by 28
Emerging therapeutic strategies for optic nerve regeneration
Zhang, Q., Tang, J., Liu, L., Liu, Z., Xue, J., Ge, J., Zhuo, Y., & Li, Y. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.11.008 · Cited by 30
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 30
He, Y., Tu, X., Xue, Y., Chen, Y., Ye, B., Li, X., Li, D., Zhong, Z., & Zhong, Q. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101357 · Cited by 31
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 31
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“…reported in up to 50 % of patients receiving Good Manufacturing Practice (GMP)-grade gene therapy products in clinical trials (Fischer et al., 2019; Reichel et al., 2022a; MacLaren et al., 2023; Pierce et al., 2024; Yang et al., 2024b; Cehajic-Kapetanovic et al., 2024; Campochiaro et al., 2024).”
InfluentialSelf-citationFrom bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases
Zhao, Q., Wei, L., & Chen, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107638 · Cited by 23
Reis, L. M., Seese, S. E., Costakos, D. M., & Semina, E. V. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101288 · Cited by 22
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
Palaz, F., Özsöz, M., Zarrinpar, A., & Şahin, İ. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s456683 · Cited by 21
Ashworth, K. E., Weisbrod, J., & Ballios, B. G. (2024) · Genes · doi:10.3390/genes15060705 · Cited by 19
Targeted delivery of genome editors in vivo
Ngo, W., Wu, J. L. Y., Wasko, K. M., & Doudna, J. A. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02945-w · Cited by 18
In vivo evaluation of guide-free Cas9-induced safety risks in a pig model
Ge, W., Gou, S., Zhao, X., Jin, Q., Zhuang, Z., Zhao, Y., Liang, Y., Ouyang, Z., Liu, X., Chen, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01905-1 · Cited by 17
Gene editing and CRISPR-dependent homology-mediated end joining
Ruis, B. L., Bielinsky, A., & Hendrickson, E. A. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01442-z · Cited by 20
Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery
Gil, J.-S., Lee, S., & Koo, T. (2025) · Gene Therapy · doi:10.1038/s41434-025-00573-2 · Cited by 19
Bairqdar, A., Karitskaya, P. E., & Stepanov, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413321 · Cited by 17
Chey, Y. C. J., Gierus, L., Lushington, C., Arudkumar, J., Geiger, A., Staker, L. G., Robertson, L. J., Pfitzner, C., Kennedy, J. G., Lee, R. H. B., et al. (2025) · BMC Genomics · doi:10.1186/s12864-025-11317-2 · Cited by 16
Liu, T., Wendel, B. J., Huey, J., Pandiyan, V. P., Mustafi, D., Chao, J. R., & Sabesan, R. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.032 · Cited by 15
The relevance of primary cilia in neurological disorders
Serpieri, V., D’Abrusco, F., & Valente, E. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00226-1 · Cited by 15
Duncan, J. L., Bowman, A. N., Laster, A., Gelfman, C. M., Birch, D. G., Boye, S. L., Daiger, S. P., Priore, L. V. D., Zack, D. J., & Handa, J. T. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.12.28 · Cited by 15
Gene therapy strategies in ophthalmology—an overview of current developments and future prospects
Krajewska, J. B., & Waszczykowska, A. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00973-5 · Cited by 18
Oshitari, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910485 · Cited by 15
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 15
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 13
Tachida, Y., Manian, K. V., Butcher, R. M., Levy, J. M., Pendse, N. D., Hennessey, E., Liu, D. R., Pierce, E. A., Liu, Q., & Comander, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.042 · Cited by 13
Self-citationEngineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
Measurement and clinical interpretation of CRISPR off-targets
Stewart, A. A., Ahrens‐Nicklas, R. C., Tsai, S. Q., Musunuru, K., Giannikopoulos, P., & Clelland, C. D. (2025) · Nature Genetics · doi:10.1038/s41588-025-02428-3 · Cited by 13
Monitoring biological effects of somatic cell genome editing
Freedman, B., Bulte, J. W. M., Conklin, B. R., Judge, L. M., Dwinell, M. R., Geurts, A. M., Sitton, M. J., Mahajan, V., Kiani, S., Gersbach, C. A., et al. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00916-0 · Cited by 13
Insights into eye genetics and recent advances in ocular gene therapy
Szabó, V., Varsányi, B., Barboni, M. T. S., Takács, Á. I., Knézy, K., Molnár, M. J., Nagy, Z. Z., György, B., & Rivolta, C. (2025) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2025.102008 · Cited by 13
In vivo delivery systems for CRISPR genome editing: Viral and non-viral carriers
Lee, Y., Kim, B., Lee, D., Cheon, S. Y., Lim, S. G., Kim, Y., & Koo, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0228874 · Cited by 13
Chronic In Vivo CRISPR-Cas Genome Editing: Challenges, Long-Term Safety, and Outlook
Bao, C., Channell, C. I., Tseng, Y.-H., Bailey, J., Sbaiti, N., Demirkol, A., & Tsang, S. H. (2026) · Cells · doi:10.3390/cells15020156 · Cited by 14
Shining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 14
Cao, M., Zhang, X., Liu, S., Wang, S., Li, X., Zhang, X., Li, B., & Huang, H. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.137007 · Cited by 11
The dark and bright sides of retinal G protein-coupled receptor (RGR) in vision and disease
Ruddin, G., McCann, T., Fehilly, J. D., Kearney, J., & Kennedy, B. N. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101339 · Cited by 9
Paradigm of nanophotonics integrated smart contact lenses: A new frontier in wearable healthcare
Taha, B. A., Abdulateef, S. A., Addie, A. J., Muneam, S. A., Muneam, N. A., Haider, A. J., Ahmed, N. M., Chaudhary, V., & Arsad, N. (2025) · Materials Research Bulletin · doi:10.1016/j.materresbull.2025.113511 · Cited by 9
Retinal photoreceptor cilia and ciliopathies: Molecular mechanisms and therapeutic strategies
Li, L., Zhou, J., & Ran, J. (2025) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2025.103635 · Cited by 9
Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders
Jony, M. J. H., Joshi, A., Dash, A. K., & Shukla, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010087 · Cited by 10
Hinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 10
Retinitis Pigmentosa: From Genetic Insights to Innovative Therapeutic Approaches—A Literature Review
Calderón, R. A. M., Emanuelli, A., & Izquierdo, N. (2025) · Medicina · doi:10.3390/medicina61071179 · Cited by 9
Nonsense-mediated mRNA decay: a key regulatory system engaged in cancer
Pan, H., Wu, X., Hu, B., Xiong, H., Luo, Y., & Zhou, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02503-6 · Cited by 8
Jiang, Y., Liu, X., Fu, J., Wu, Y., Yu, S., & Yao, K. (2025) · Biomolecules · doi:10.3390/biom15111624 · Cited by 8
Tsukamoto, T., Mizuta, H., Sakai, E., Sakurai, F., & Mizuguchi, H. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.029 · Cited by 8
Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Tang, A., & Yokota, T. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2447072 · Cited by 8
Inactivation of the key ORFs of HBV for antiviral therapy by non-cleavage base editing
Qin, B., Shěn, S., Chen, H., Wang, Y., Ding, J., & Ding, J. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107689 · Cited by 7
Alternative Splicing Regulation in Metabolic Disorders
Kamińska, D. (2025) · Obesity Reviews · doi:10.1111/obr.13950 · Cited by 7
Functional vision tests as clinical trial outcome measures in ophthalmology: a scoping review
Raji, S., Thirunavukarasu, A. J., Taylor, L. J., & MacLaren, R. E. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097970 · Cited by 7
AlEissa, M. M., Alhawsawi, A. A., Alonazi, R. H., Magharbil, E., Aljahdali, A., ALBalawi, H. B., Alali, N. M., Hameed, S., Abu‐Amero, K. K., & Magliyah, M. (2025) · Genes · doi:10.3390/genes16070847 · Cited by 7
Non-clinical safety considerations on genome editing using the CRISPR/Cas system
Toofan, P., Singh, M., Brööks, A. G., & McLuckie, K. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101785 · Cited by 6
Thompson, D. A., Jayasundera, T., Alekseev, O., Ali, R. R., Amato, A., Arshavsky, V. Y., Audo, I. S., Auricchio, A., Bainbridge, J. W., Banin, E., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.8.37 · Cited by 8
Self-citationUpdate on Gene Therapy Clinical Trials for Eye Diseases
Lonfat, N., Leon, L. M., Punzo, C., & Khanna, H. (2025) · Human Gene Therapy · doi:10.1177/10430342251379824 · Cited by 7
Zhang, H., Li, Y., Li, J., Li, X., & Li, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111405 · Cited by 8
AAV-mediated expression of proneural factors stimulates neurogenesis from adult Müller glia in vivo
Pavlou, M., Probst, M., Kaplan, L., Filippova, E., Prieve, A., Rieke, F. M., & Reh, T. A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00209-3 · Cited by 16
Innovative therapies for inherited retinal dystrophies: navigating DNA, RNA, and protein approaches
Gómez-Escribano, A. P., García-García, G., Pérez-Santamarina, E., Aller-Mañas, E., Vázquez-Manrique, R. P., & Millán-Salvador, J. M. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105751 · Cited by 6
“…pro fi le and variable effectiveness of visual functional outcomes (retinal sensitivity, visual acuity, Ora – Visual Navigation Challenge) in Phase 1/2 of a small cohort of 14 participants (NCT03872479), 64 which is ongoing with a larger cohort (34 participants) to con fi rm ef fi cacy (Table 1).”
Vázquez-Domínguez, I., Öktem, M., Winkelaar, F. A., Nguyen, T. H., Hoogendoorn, A. D. M., Roschi, E., Astuti, G., Timmermans, R., Suárez-Herrera, N., Bruno, I., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102345 · Cited by 7
The path to biotechnological singularity: Current breakthroughs and outlook
Wen, Z., Yang, D., Yang, Y., Hu, J., Parviainen, A., Chen, X., Li, Q., VanDeusen, E. A., Ma, J., & Tay, F. R. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108667 · Cited by 7
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
A clinical roadmap for base and prime editing
Flugel, C. L., Cadiñanos-Garai, A., & Abou‐El‐Enein, M. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00360-z · Cited by 6
Huang, Y., Pang, S., Li, L., Do, C. W., Luo, Q., 郑宗立, & Xiong, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114499 · Cited by 10
Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development
Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 7
Wang, Q. K., Xu, X., Chen, S., Lu, R., Li, L., Lo, C., Liu, Z., Ning, K., Li, T., Kowal, T. J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn7540 · Cited by 6
Murakami, Y., Hisai, T., Shimokawa, S., Fukushima, M., Fujiwara, K., Hirata, A., Takada, A., Miyahara, F., Nakashima, N., Kobayakawa, Y., et al. (2025) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-025-01179-2 · Cited by 6
Senior–Loken Syndrome: Ocular Perspectives on Genetics, Pathogenesis, and Management
Zhou, D., Zeng, Y., Luo, W., Leng, C., & Li, C. (2025) · Biomolecules · doi:10.3390/biom15050667 · Cited by 7
In vivo genome editing for inherited retinal disease: Opportunities and challenges
Collin, R. W. J., & Leroy, B. P. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.001 · Cited by 6
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 9
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 6
CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., et al. (2026) · Cells · doi:10.3390/cells15070644 · Cited by 5
Gene therapy shines light on congenital stationary night blindness for future cures
Zhang, Y., Lin, S., Yu, L., Lin, X. Y., Qu, S., Ye, Q., Yu, M., Chen, W., & Wu, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06392-8 · Cited by 4
Qian, Y., Gao, J. H., Zhang, Z., Chen, Y., Su, J., Niu, X., Zheng, K., Bao, Y., Qin, Y., Zheng, J., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107724 · Cited by 5
Eyes shut homolog (EYS): Connecting molecule to disease
Marques, J. P., Sousa, I. S., Patrício, D., Simões, B. F., Chukwunalu, O., Zeitz, C., Audo, I. S., Collin, R. W. J., Quinn, P. M. J., Ambrósio, A. F., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101391 · Cited by 5
Elasal, M. A., Mousa, S., Salameh, M., Blumenfeld, A., Khateb, S., Banin, E., & Sharon, D. (2024) · Genes · doi:10.3390/genes15070926 · Cited by 5
Tackling visual impairment: emerging avenues in ophthalmology
Lin, F., Su, Y., Zhao, C., Akter, F., Yao, S., Huang, S., Shao, X., & Yao, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1567159 · Cited by 6
A Milestone for Gene-Editing Therapies
Musunuru, K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2412176 · Cited by 5
CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential
Wei, Y., Sun, J. Y., & Zhu, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.031 · Cited by 5
CRISPR–Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis
Ishida, S., Sato, Y., Chosa, K., Ezawa, E., Yamauchi, Y., Oyama, M., Kozuka‐Hata, H., Ito, R., Sato, R., Maeki, M., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02949-6 · Cited by 5
Gene therapy for choroideremia: progress, potential and pitfalls
Elsayed, M. E. A. A., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2459850 · Cited by 4
RPE65 Variant p.(E519K) Causes a Novel Dominant Adult-Onset Maculopathy in 83 Affected Individuals
Vooren, E. V., den Broeck, F. V., Mahieu, Q., Geens, E., Heetvelde, M. V., Bruyne, M. D., de Sompele, S. V., Uppal, S., Poliakov, E., Dhaenens, C., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.53 · Cited by 5
Antisense oligonucleotides for inherited retinal diseases: a comprehensive review
Banadaki, H. D., Garanto, A., & Collin, R. W. J. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101416 · Cited by 4
Butt, F. R., Dhivagaran, T., Li, B., Ashamalla, M., Tao, B. K.-L., Balas, M., Pereira, A., Yan, P., & Arjmand, P. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120619 · Cited by 6
Engineering CRISPR for emerging therapeutic applications
Sun, X., & Liu, Z. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100035 · Cited by 4
Alemán, T. S., Uyhazi, K. E., Román, A. J., Weber, M. L., O'Neil, E. C., Świder, M., Sumaroka, A., Maguire, K. H., Aleman, E. M., Santos, A. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.035 · Cited by 6
Self-citationMatczyńska, E., Szymańczak, R., Stradomska, K., Łyszkiewicz, P., Jędrzejowska, M., Kamińska, K., Beć-Gajowniczek, M., Suchecka, E., Zagulski, M., Wiącek, M. P., et al. (2024) · Genes · doi:10.3390/genes15081011 · Cited by 3
Gene Therapy Strategies for the Treatment of Bestrophinopathies
Hansen, S., McClements, M. E., Cehajic‐Kapetanovic, J., Corydon, T. J., & MacLaren, R. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199421 · Cited by 3
Therapeutic base editing to generate a gain-of-function F9 variant for hemophilia B
Baatartsogt, N., Kashiwakura, Y., Hiramoto, T., Ito, R., Sato, R., Nagao, Y., Naruoka, H., Takata, H., Hayakawa, M., Batjargal, K., et al. (2025) · Blood · doi:10.1182/blood.2024027870 · Cited by 3
Genetics and eye health: research advances and implications for primary eyecare
Britten‐Jones, A. C., Knight, L. S. W., Gocuk, S. A., Truong, P., Cichello, E., Amarasekera, S. S. C., Nguyen, B. N., & Ayton, L. N. (2025) · Clinical and Experimental Optometry · doi:10.1080/08164622.2025.2580576 · Cited by 3
Hisai, T., Murakami, Y., Kusano, K., Kobayakawa, Y., & Ikeda, Y. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4807-0_20 · Cited by 3
Minimizing far-extending chromatin perturbation in genome editing preserves stem cell identity
Zhu, M., Yuan, J., Meng, Q., Yu, J., Xu, X., Xu, M., Ren, X., Hu, Y., Wei, G., Jia, Z., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.01.015 · Cited by 3
Xu, P., Guo, F., Wang, Y., Chen, G., Song, X., Luo, B. Y., Zheng, D., Gao, G., Yin, W., Zhang, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.040 · Cited by 3
Cideciyan, A. V., Román, A. J., Warner, R. L., Sumaroka, A., Wu, V. F., Jiang, Y. Y., Świder, M., Garafalo, A. V., Viarbitskaya, I., Russell, R. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910639 · Cited by 3
Gong, X., & Hertle, R. W. (2024) · Life · doi:10.3390/life14111356 · Cited by 3
Major, R., Mills, C. A., Xing, L., Krantz, J. L., Wolter, J. M., & Zylka, M. J. (2025) · The CRISPR Journal · doi:10.1089/crispr.2024.0074 · Cited by 3
Metadata
- Authors
- Pierce, E. A., Aleman, T. S., Jayasundera, K. T., Ashimatey, B. S., Kim, K., Rashid, A., Jaskolka, M. C., Myers, R. L., Lam, B. L., Bailey, S. T., Comander, J. I., Lauer, A. K., Maguire, A. M., & Pennesi, M. E.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- From the Ocular Genomics Institute, Department of Ophthalmology, Mass Eye and Ear and Harvard Medical School, Boston (E.A.P., J.I.C.), and Editas Medicine, Cambridge (B.S.A., K.K., A.R., M.C.J., R.L.M.) — both in Massachusetts; the Scheie Eye Institute and the Division of Ophthalmology of the Children’s Hospital of Philadelphia, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (T.S.A., A.M.M.); the University of Michigan Kellogg Eye Center, Ann Arbor (K.T.J.); the Bascom Palmer Eye Institute, University of Miami, Miami (B.L.L.); and the Casey Eye Institute, Oregon Health and Science University, Portland (S.T.B., A.K.L., M.E.P.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-06-06
- Volume
- 390
- Issue
- 21
- Pages
- 1972-1984
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11389875
- OpenAlex
- W4396676517
- Cited by
- 237
- References
- 41
- Citations by year
- 2026: 101 · 2025: 103 · 2024: 33
- FWCI
- 31.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Malcolm M. Marquis MD Endowed Fund for Innovation
- Research to Prevent Blindness
- Irene Heinz Given and John La Porte Given Endowment
- Hope For Vision
- National Eye Institute (P30 EY010572, P30 EY014104)
- Editas Medicine
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- CRISPR/Cas9 genome editing, subretinal injection, photoreceptor function, best-corrected visual acuity, retinal sensitivity, vision-related quality of life, children, compound heterozygosity
- MeSH terms
- Gene Editing, Adolescent, Adult, Antigens, Neoplasm, Cytoskeletal Proteins, Female, Humans, Male, Middle Aged, Quality of Life, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Cell Cycle Proteins, Young Adult, Injections, Intraocular, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
